Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma
Department of Quantitative Health Sciences
Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; effects; Cyclophosphamide; Dactinomycin; Drug Evaluation; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Mitolactol; Semustine
Biostatistics | Epidemiology | Health Services Research
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
Rights and Permissions
Citation: Invest New Drugs. 1987;5(3):293-7. Link to article on publisher's site
Investigational new drugs
Amato, David A.; Bruckner, Howard; Guerry, DuPont IV; Ash, Arlene S.; Falkson, Geoffrey; Borden, Ernest C.; Creech, Richard H.; Savlov, Edwin D.; and Cunningham, Thomas J., "Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma" (1987). Quantitative Health Sciences Publications and Presentations. 620.